Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.